The Boston company will use the new investment to continue scaling its virtual care business. Biofourmis also announced that medtech veteran Omar Ishrak is joining the company’s board as its chairman.

While many of his peers elbowed each other to leap into oncology, James Xue decided to focus on rare diseases such as Hunter’s Syndrome. Now, 10 years after founding CANbridge, the CEO sat down for an audio interview with Scrip to offer his views on a flurry of key issues impacting orphan drug development in potentially the world's largest pharma market.

Pfizer’s acquisition of Arena without FTC intervention and Hikma’s acquisition of Custopharm with one product divestiture shows the commission is bound by anticompetitive facts of a deal. A more controversial merger may not get through, former FTC attorney says.

Carbogen, Advanz and Perrigo have all announced significant changes to their C-suite staff, while several firms have announced changes to their executive and advisory boards.